Y Intercept Hong Kong Ltd Takes Position in Amylyx Pharmaceuticals, Inc. (NASDAQ:AMLX)

Y Intercept Hong Kong Ltd bought a new stake in shares of Amylyx Pharmaceuticals, Inc. (NASDAQ:AMLX) during the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund bought 14,809 shares of the company’s stock, valued at approximately $56,000.

A number of other hedge funds have also recently modified their holdings of the business. Blue Trust Inc. boosted its holdings in shares of Amylyx Pharmaceuticals by 232.1% during the 4th quarter. Blue Trust Inc. now owns 6,987 shares of the company’s stock valued at $26,000 after buying an additional 4,883 shares in the last quarter. JPMorgan Chase & Co. boosted its holdings in shares of Amylyx Pharmaceuticals by 144.4% during the 3rd quarter. JPMorgan Chase & Co. now owns 140,559 shares of the company’s stock valued at $455,000 after buying an additional 83,048 shares in the last quarter. Barclays PLC boosted its stake in Amylyx Pharmaceuticals by 91.1% in the 3rd quarter. Barclays PLC now owns 84,572 shares of the company’s stock worth $274,000 after purchasing an additional 40,319 shares in the last quarter. Geode Capital Management LLC boosted its stake in Amylyx Pharmaceuticals by 17.5% in the 3rd quarter. Geode Capital Management LLC now owns 551,039 shares of the company’s stock worth $1,786,000 after purchasing an additional 82,173 shares in the last quarter. Finally, Walleye Capital LLC boosted its stake in Amylyx Pharmaceuticals by 986.5% in the 3rd quarter. Walleye Capital LLC now owns 670,594 shares of the company’s stock worth $2,173,000 after purchasing an additional 608,874 shares in the last quarter. Institutional investors own 95.84% of the company’s stock.

Insiders Place Their Bets

In other news, CEO Justin B. Klee sold 7,471 shares of the company’s stock in a transaction dated Monday, January 6th. The shares were sold at an average price of $4.04, for a total transaction of $30,182.84. Following the completion of the sale, the chief executive officer now owns 3,176,788 shares of the company’s stock, valued at $12,834,223.52. This represents a 0.23 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, CEO Joshua B. Cohen sold 11,851 shares of the company’s stock in a transaction dated Monday, February 3rd. The shares were sold at an average price of $3.47, for a total transaction of $41,122.97. Following the sale, the chief executive officer now directly owns 3,201,247 shares of the company’s stock, valued at $11,108,327.09. The trade was a 0.37 % decrease in their position. The disclosure for this sale can be found here. In the last 90 days, insiders sold 27,169 shares of company stock valued at $97,274. 11.70% of the stock is owned by insiders.

Analyst Upgrades and Downgrades

A number of equities analysts recently issued reports on AMLX shares. Robert W. Baird upgraded shares of Amylyx Pharmaceuticals from a “neutral” rating to an “outperform” rating and upped their price target for the stock from $3.00 to $11.00 in a research note on Monday, November 18th. HC Wainwright reiterated a “buy” rating and issued a $12.00 price target on shares of Amylyx Pharmaceuticals in a research note on Wednesday. Finally, Baird R W upgraded shares of Amylyx Pharmaceuticals from a “hold” rating to a “strong-buy” rating in a research note on Monday, November 18th. Five equities research analysts have rated the stock with a hold rating, three have assigned a buy rating and one has given a strong buy rating to the company. According to MarketBeat, the stock has a consensus rating of “Moderate Buy” and a consensus price target of $7.33.

Amylyx Pharmaceuticals Stock Performance

Shares of NASDAQ:AMLX opened at $3.36 on Thursday. Amylyx Pharmaceuticals, Inc. has a fifty-two week low of $1.58 and a fifty-two week high of $19.32. The business has a 50-day simple moving average of $3.54 and a two-hundred day simple moving average of $3.86. The firm has a market cap of $230.32 million, a price-to-earnings ratio of -0.88 and a beta of -0.54.

Amylyx Pharmaceuticals (NASDAQ:AMLX) last issued its earnings results on Tuesday, March 4th. The company reported ($0.55) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.49) by ($0.06). The business had revenue of ($0.67) million during the quarter. As a group, research analysts predict that Amylyx Pharmaceuticals, Inc. will post -2.2 earnings per share for the current year.

Amylyx Pharmaceuticals Company Profile

Amylyx Pharmaceuticals, Inc, a commercial-stage biotechnology company, engages in the discovery and development of treatment for amyotrophic lateral sclerosis (ALS) and neurodegenerative diseases. The company's products include RELYVRIO, a dual UPR-Bax apoptosis inhibitor composed of sodium phenylbutyrate and taurursodiol for the treatment of ALS in adults in the United States and marketed as ALBRIOZA for the treatment of ALS in Canada.